Breelyn A. Wilky, MD, of the Sylvester Comprehensive Cancer Center, Miami, Fl, gives us an overview of the current immunotherapy treatment landscape for sarcoma. Although over the past few years, people have started to explore how immunotherapy can be used for sarcomas, there is still a lot that is unknown. She explains that we are just starting to learn about what immune cells might be inside of the tumour deposits. A recent paper has suggested there could be a genetic immunosignature that may be a better biomarker for immune activity compared to traditional markers like PL1. Dr. Wilky mentions several different ways that the immune system can be targeted. These include vaccine therapy, adopted T cell therapy and various combination studies that are incorporating checkpoint inhibitors with other agents. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
